Reduction of HIV persistence following transplantation in HIV-infected kidney transplant recipients

American Journal of Transplantation

Volumn 14, Issue 5, 2014, Pages 1136-1141

  Stock, P G ^a   Barin, B ^b   Hatano, H ^a   Rogers, R L ^a   Roland, M E ^a   Lee, T H ^c   Busch, M ^c   Deeks, S G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b EMMES CORPORATION   (United States)

^c BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

Author keywords

Human immunodeficiency virus; kidney transplantation; sirolimus

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; VIRUS RNA;

BLOOD; CD4+ T LYMPHOCYTE; COMPLICATION; DRUG EFFECTS; FEMALE; FOLLOW UP; GENETICS; GRAFT RECIPIENT; GRAFT SURVIVAL; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; ISOLATION AND PURIFICATION; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; VIROLOGY;

CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HIV; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RNA, VIRAL; SURVIVAL RATE; TRANSPLANT RECIPIENTS;

EID: 84899449343     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12699     Document Type: Article

References (39)

1. Deeks SG, Autran B, Berkhout B, et al. Towards an HIV cure: A global scientific strategy. Nat Rev Immunol 2012; 12: 607-614.
2. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360: 692-698.
3. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9: 727-728.
4. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ., The challenge of finding a cure for HIV infection. Science 2009; 323: 1304-1307.
5. Trono D, Van Lint C, Rouzioux C, et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010; 329: 174-180.
6. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201: 1788-1795.
7. Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17: 1907-1915.
8. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15: 893-900.
9. Hatano H, Jain V, Hunt PW, et al. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis 2013; 208: 50-56.
10. Klatt NR, Chomont N, Douek DC, Deeks SG., Immune activation and HIV persistence: Implications for curative approaches to HIV infection. Immunol Rev 2013; 254: 326-342.
11. Isotani S, Hara K, Tokunaga C, Inoue H, Avruch J, Yonezawa K., Immunopurified mammalian target of rapamycin phosphorylates and activates p70 S6 kinase alpha in vitro. J Biol Chem 1999; 274: 34493-34498.
12. Gamper CJ, Powell JD., All PI3Kinase signaling is not mTOR: Dissecting mTOR-dependent and independent signaling pathways in T cells. Front Immunol 2012; 3: 312.
13. Wiederrecht GJ, Sabers CJ, Brunn GJ, Martin MM, Dumont FJ, Abraham RT., Mechanism of action of rapamycin: New insights into the regulation of G1-phase progression in eukaryotic cells. Prog Cell Cycle Res 1995; 1: 53-71.
14. Battaglia M, Stabilini A, Roncarolo MG., Rapamycin selectively expands CD4+ CD25+ FoxP3+ regulatory T cells. Blood 2005; 105: 4743-4748.
15. Lee YR, Yang IH, Lee YH, et al. Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood 2005; 105: 3951-3955.
16. Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460: 108-112.
17. Keating R, Hertz T, Wehenkel M, et al. The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nat Immunol 2013; 14: 1266-1276.
18. Baan CC, van der Mast BJ, Klepper M, et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005; 80: 110-117.
19. Coenen JJ, Koenen HJ, Rijssen EV, Hilbrands LB, Joosten I., Rapamycin, and not cyclosporin A preserves the highly suppressive CD27+ subset of human CD4+ CD25+ regulatory T cells. Blood 2006; 107: 1018-1023.
20. Donia M, McCubrey JA, Bendtzen K, Nicoletti F., Potential use of rapamycin in HIV infection. Br J Clin Pharmacol 2010; 70: 784-793.
21. Heredia A, Amoroso A, Davis C, et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: An approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci U S A 2003; 100: 10411-10416.
22. Mulampaka SN, Dixit NM., Estimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusion. PLoS ONE 2011; 6: e19941.
23. Gilliam BL, Heredia A, Devico A, et al. Rapamycin reduces CCR5 mRNA levels in macaques: Potential applications in HIV-1 prevention and treatment. AIDS 2007; 21: 2108-2110.
24. Zhou D, Kang KH, Spector SA., Production of interferon alpha by human immunodeficiency virus type 1 in human plasmacytoid dendritic cells is dependent on induction of autophagy. J Infect Dis 2012; 205: 1258-1267.
25. Krown SE, Roy D, Lee JY, et al. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: An AIDS Malignancy Consortium study. J Acquir Immune Defic Syndr 2012; 59: 447-454.
26. Zhou D, Spector SA., Human immunodeficiency virus type-1 infection inhibits autophagy. AIDS 2008; 22: 695-699.
27. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363: 2004-2014.
28. Hunt PW, Hatano H, Sinclair E, et al. HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers. Clin Infect Dis 2011; 52: 681-687.
29. Hatano H, Hayes TL, Dahl V, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 2011; 203: 960-968.
30. Hunt PW, Landay AL, Sinclair E, et al. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS ONE 2011; 6: e15924.
31. Hatano H, Delwart EL, Norris PJ, et al. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS 2010; 24: 2535-2539.
32. Hatano H, Delwart EL, Norris PJ, et al. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 2009; 83: 329-335.
33. Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004; 351: 760-768.
34. Stekler J, Swenson PD, Wood RW, Handsfield HH, Golden MR., Targeted screening for primary HIV infection through pooled HIV-RNA testing in men who have sex with men. AIDS 2005; 19: 1323-1325.
35. Lelie PN, van Drimmelen HA, Cuypers HT, et al. Sensitivity of HCV RNA and HIV RNA blood screening assays. Transfusion 2002; 42: 527-536.
36. Busch MP, Glynn SA, Wright DJ, et al. Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection. Transfusion 2005; 45: 1853-1863.
37. Bernardin F, Tobler L, Walsh I, Williams JD, Busch M, Delwart E., Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia. Hepatology 2008; 47: 1446-1452.
38. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187: 1534-1543.
39. Ho YC, Shan L, Hosmane NN, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013; 155: 540-551.